MA MAXHEALTH
Max Healthcare Institute Q2 2027
MAMAXHEALTH

Max Healthcare Institute Q2 FY27 results (Jul–Sep 2026) and concall

Healthcare · Concall AI · Call held 3 Nov 2026

Management summary

  • Max Healthcare delivered strong operational performance in Q2 FY27, with gross revenue growing 20% YoY to ₹3,219 crore and operating EBITDA rising 18% YoY to ₹820 crore, sustaining a healthy 26.8% EBITDA margin.
  • Growth was underpinned by stable 77% occupancy despite a 14% YoY increase in operational beds, alongside an 8% increase in IP ARPP to ₹2.31 lakhs.
  • Brownfield ramp-ups at Max Smart Saket, Max Mohali, and Max Nanavati progressed well, with Board approval secured for an additional ₹415 crore brownfield expansion across Noida, Vaishali, and BLK-Max.

Source: Inve concall analysis and management guidance record.

Highlights

  • Network gross revenue grew 20% YoY to ₹3,219 crore, and Operating EBITDA grew 18% YoY to ₹820 crore

  • International patient revenue jumped 33% YoY to ₹307 crore, contributing 10% of hospital healthcare revenue

  • Free cash flow generation was strong at ₹500 crore for Q2 FY27 (₹897 crore in H1 FY27)

  • Strategic business units Max@Home and Max Lab delivered robust revenue growth of 37% (₹86 crore) and 24% (₹66 crore) YoY, respectively

What they filed

Q2 FY27: revenue up 20.3%, net profit down 15.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue1,868 1,910 2,028 2,135 2,068 +11%2,143 +12%2,366 +17%2,569 +20%
EBITDA499 512 523 575 538 +8%606 +18%598 +14%711 +24%
Net profit239 319 308 491 301 +26%342 +7%323 +5%414 −16%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Capacity

  • Operational Bed Commissioning - Max Nanavati and Max Smart Capacity · Q3 FY27 (post Diwali puja) · High confidence 205 beds
  • Operational Bed Commissioning - Max Dwarka Oncology Block Capacity · Q3 FY27 · High confidence 20 beds

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct, 1 evasive
Impact of trade margin caps on non-scheduled drugs and hospital margins Evasive
We are still working it out... The matter is sub judice. And I think it is quite clear what the position of the hospital providers is and so is the position of the Government.

Management avoided quantifying the financial downside from potential trade margin caps or unbundling pharmacy revenue, noting the matter remains in court.

Asked by Tausif Shaikh / Neha Manpuria / Dhara Ganatra

De-empanelment of institutional schemes (CGHS/ECHS/Railways) at mature hospitals Direct
So, we de-empanelled BLK in May for CGHS and then the Railways, etc., because they were not paying us. We also de-empanelled ECHS at Shalimar Bagh... The more mature hospitals or older hospitals, you see them de-empanelling and distilling their payor mix, whilst the newer hospita

Reveals active pruning of slow-paying institutional schemes at capacity-constrained legacy hospitals to optimize ARPOB and receivables.

Asked by Tausif Shaikh

Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 6 risks, concerns & management red flags
  • 4 watchlist triggers for Q3 FY27
  • +16 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image